Leading the Way in Life Science Technologies

GEN Exclusives

More »

Sidebars

More »
Mar 15, 2009 (Vol. 29, No. 6)

Novel OncoMouse Model

  • Caliper Discovery Alliances & Services (CDAS), which offers multiple tumor models for preclinical cancer research, reports that it recently developed a pancreatic OncoMouse® model—EL1-luc/EL1-SV40 T-antigen transgenic—to overcome some disadvantages of xenograft tumor models, such as the use of immuno-compromised mice. Through a specific agreement with DuPont Intellectual Assets & Licensing (see January 1 GEN, page 16), CDAS says it can now provide preclinical in vivo compound efficacy and research studies using spontaneous tumor models linking an activated oncogene with a bioluminescent reporter system. It is now possible for scientists to study drug effects in the more relevant physiological microenvironment context of a nonimmnuno-compromised animal, which will better recapitulate the effect of the drug in humans, according to a CDAS official.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »